Top

Published in:

01-05-2019 | Metastasis | Endocrine Tumors

Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately

Authors: Tsukasa Yoshida, MD, Susumu Hijioka, MD, PhD, Waki Hosoda, MD, PhD, Makoto Ueno, MD, Masayuki Furukawa, MD, PhD, Noritoshi Kobayashi, MD, PhD, Masafumi Ikeda, MD, Tetsuhide Ito, MD, PhD, Yuzo Kodama, MD, PhD, Chigusa Morizane, MD, PhD, Kenji Notohara, MD, PhD, Hiroki Taguchi, MD, PhD, Masayuki Kitano, MD, PhD, Kei Yane, MD, Yoshiaki Tsuchiya, MD, Izumi Komoto, MD, PhD, Hiroki Tanaka, MD, Akihito Tsuji, MD, PhD, Syunpei Hashigo, MD, Tetsuya Mine, MD, PhD, Atsushi Kanno, MD, PhD, Go Murohisa, MD, PhD, Katsuyuki Miyabe, MD, PhD, Tadayuki Takagi, MD, PhD, Nobutaka Matayoshi, MD, Masafumi Sakaguchi, MD, Hiroshi Ishii, MD, Yasushi Kojima, MD, PhD, Keitaro Matsuo, MD, PhD, Hideyuki Yoshitomi, MD, PhD, Shoji Nakamori, MD, PhD, Hiroaki Yanagimoto, MD, PhD, Yasushi Yatabe, MD, PhD, Junji Furuse, MD, PhD, Nobumasa Mizuno, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2019

Abstract

Background

The role of surgery in pancreatic neuroendocrine neoplasm grade 3 (pNEN-G3) treatment remains unclear. We aimed to clarify the role of surgery for pNEN-G3, which has recently been reclassified as pancreatic neuroendocrine tumor-G3 (pNET-G3) and pancreatic neuroendocrine carcinoma-G3 (pNEC-G3), with and without metastases, respectively.

Methods

We analyzed a subgroup of patients from the Japanese pancreatic NEC study, a Japanese multicenter case-series study of pNEN-G3. Pathologists subclassified 67 patients as having pNET-G3 or pNEC-G3 based on morphological features. We compared the overall survival (OS) rates among patients who were grouped according to whether they had undergone tumor-targeted surgery for tumors without (SwoM) or with (SwM) metastases, or non-surgical procedures (NS).

Results

Data from 21 patients with pNET-G3 (SwoM, n = 6; SwM, n = 5; NS, n = 10) and 46 patients with pNEC-G3 (SwoM, n = 8; SwM, n = 5; NS, n = 33) were analyzed. OS of patients with pNET-G3 was significantly longer after SwoM and SwM than with NS (p = 0.018 and p = 0.022). In contrast, OS did not significantly differ between either SwoM or SwM and NS (p = 0.093 and p = 0.489) among patients with pNEC-G3.

Conclusion

The role of surgery should be considered separately for pNET-G3 and pNEC-G3. Although SwoM and SwM can be considered for pNET-G3, caution is advised before considering SwM and SwoM for pNEC-G3.

Basturk O, Tang L, Hruban RH, et al. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol. 2014;38(4):437–47.CrossRefPubMedPubMedCentral

Basturk O, Yang Z, Tang LH, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015;39(5):683–90.CrossRefPubMedPubMedCentral

Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36(2):173–84.CrossRefPubMedPubMedCentral

Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–60.CrossRefPubMed

Reid MD, Balci S, Saka B, Adsay NV. Neuroendocrine tumors of the pancreas: current concepts and controversies. Endocr Pathol. 2014;25(1):65–79.CrossRefPubMed

Heetfeld M, Chougnet CN, Olsen IH, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22(4):657–64.CrossRefPubMed

Velayoudom-Cephise FL, Duvillard P, Foucan L, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013;20(5):649–57.CrossRefPubMed

Hijioka S, Hosoda W, Mizuno N, et al. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas? J Gastroenterol. 2015;50(5):564–72.CrossRefPubMed

Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2017.

10.

Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, et al. NCCN guidelines version 2.2016: neuroendocrine tumor of the pancreas. National Comprehensive Cancer Network; 2016.

11.

Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39(6):799–800.CrossRefPubMedPubMedCentral

12.

Casas F, Ferrer F, Farrus B, Casals J, Biete A. Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis. Cancer. 1997;80(8):1366–72.CrossRefPubMed

13.

Brenner B, Tang LH, Klimstra DS, Kelsen DP. Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol. 2004;22(13):2730–39.CrossRefPubMed

14.

Fischer L, Bergmann F, Schimmack S, et al. Outcome of surgery for pancreatic neuroendocrine neoplasms. Br J Surg. 2014;101(11):1405–12.CrossRefPubMed

15.

Cho CS, Labow DM, Tang L, et al. Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer. 2008;113(1):126–34.CrossRefPubMed

16.

Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, et al. NCCN guidelines version 3.2017; neuroendocrine tumors. National Comprehensive Cancer Network; 2017.

17.

Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186–94.CrossRefPubMed

18.

Hijioka S, Hosoda W, Matsuo K, et al. Rb loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: A Japanese multicenter pancreatic NEN-G3 study. Clin Cancer Res. 2017;23(16):4625–32.CrossRefPubMed

19.

Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17(12):3129–36.CrossRefPubMed

20.

Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford). 2010;12(6):427–33.CrossRefPubMedPubMedCentral

21.

Lesurtel M, Nagorney DM, Mazzaferro V, Jensen RT, Poston GJ. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford). 2015;17(1):17–22.CrossRefPubMed

22.

Huttner FJ, Schneider L, Tarantino I, et al. Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis. Langenbecks Arch Surg. 2015;400(6):715–23.CrossRefPubMed

23.

Keutgen XM, Nilubol N, Glanville J, et al. Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2016;159(1):311–18.CrossRefPubMed

24.

Hill JS, McPhee JT, McDade TP, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009;115(4):741–51.CrossRefPubMed

25.

Crippa S, Partelli S, Bassi C, et al. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters. Surgery. 2016;159(3):862–71.CrossRefPubMed

26.

Haugvik SP, Janson ET, Osterlund P, et al. Surgical treatment as a principle for patients with high-grade pancreatic neuroendocrine carcinoma: a nordic multicenter comparative study. Ann Surg Oncol. 2016;23(5):1721–28.CrossRefPubMed

27.

Partelli S, Inama M, Rinke A, et al. Long-term outcomes of surgical management of pancreatic neuroendocrine tumors with synchronous liver metastases. Neuroendocrinology. 2015;102(1–2):68–76.CrossRefPubMed

28.

Galleberg RB, Knigge U, Tiensuu Janson E, et al. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. Eur J Surg Oncol. 2017;43(9):1682–89.CrossRefPubMed

Title: Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately
Authors: Tsukasa Yoshida, MD
Susumu Hijioka, MD, PhD
Waki Hosoda, MD, PhD
Makoto Ueno, MD
Masayuki Furukawa, MD, PhD
Noritoshi Kobayashi, MD, PhD
Masafumi Ikeda, MD
Tetsuhide Ito, MD, PhD
Yuzo Kodama, MD, PhD
Chigusa Morizane, MD, PhD
Kenji Notohara, MD, PhD
Hiroki Taguchi, MD, PhD
Masayuki Kitano, MD, PhD
Kei Yane, MD
Yoshiaki Tsuchiya, MD
Izumi Komoto, MD, PhD
Hiroki Tanaka, MD
Akihito Tsuji, MD, PhD
Syunpei Hashigo, MD
Tetsuya Mine, MD, PhD
Atsushi Kanno, MD, PhD
Go Murohisa, MD, PhD
Katsuyuki Miyabe, MD, PhD
Tadayuki Takagi, MD, PhD
Nobutaka Matayoshi, MD
Masafumi Sakaguchi, MD
Hiroshi Ishii, MD
Yasushi Kojima, MD, PhD
Keitaro Matsuo, MD, PhD
Hideyuki Yoshitomi, MD, PhD
Shoji Nakamori, MD, PhD
Hiroaki Yanagimoto, MD, PhD
Yasushi Yatabe, MD, PhD
Junji Furuse, MD, PhD
Nobumasa Mizuno, MD, PhD
Publication date: 01-05-2019
Publisher: Springer International Publishing
Keywords: Metastasis
Neuroendocrine Tumor
Published in: Annals of Surgical Oncology / Issue 5/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-019-07252-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2019

Value-Based Analysis for Breast Cancer Treatment: We Don’t Know What We Don’t Know

Impact of Breast Center Accreditation on Compliance with Breast Quality Performance Measures at Commission on Cancer-Accredited Centers

Transanal Minimally Invasive Surgery (TAMIS) for Large Rectal Polyps

Comprehensive Genetic Search to Clarify the Molecular Mechanism of Drug Resistance Identifies ASCL2-LEF1/TSPAN8 Axis in Colorectal Cancer

Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy

Promising Long-Term Outcomes After Pelvic Exenteration